首页> 外文OA文献 >Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation:The Chinese Atrial Fibrillation Registry Study

【2h】

Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation:The Chinese Atrial Fibrillation Registry Study

机译：中国非瓣膜性心房颤动患者口服抗凝治疗的现状和时间趋势：中国心房颤动登记研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Chang, San-Shuai; Dong, Jian-Zeng; Ma, Chang-Sheng; Du, Xin; Wu, Jia-Hui; Tang, Ri-Bo; Xia, Shi-Jun; Guo, Xue-Yuan; Yu, Rong-Hui; Long, De-Yong; Bai, Rong; Liu, Nian; Sang, Cai-Hua; Jiang, Chen-Xi; Liu, Xiao-Hui; Pan, Jian-Hong; Lip, Gregory Y H;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation The Chinese Atrial Fibrillation Registry Study [J] . Chang San-Shuai, Dong Jian-Zeng, Ma Chang-Sheng, Stroke: A Journal of Cerebral Circulation . 2016,第7期

机译：中国非瓣膜性心房颤动患者口服抗凝药的现状和时间趋势中国心房颤动注册研究
2. Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Piccini Jonathan P., Stevens Susanna R., Chang YuChiao, Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：对有关“非瓣膜性房颤患者中风和全身性栓塞的预测指标：肾功能不全：ROCKET AF（Rivaroxaban每日一次，口服，直接因素）中的R（2）CHADS（2）指数的验证的答复Xa抑制与维生素K拮抗剂在房颤预防卒中和栓塞试验中的比较以及ATRIA（房颤的抗凝和危险因素）研究队列”
3. Letter by Apostolakis et al Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R(2)CHADS(2) Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study Cohorts" [J] . Apostolakis Stavros, Lane Deirdre A., Banerjee Amitava Circulation: An Official Journal of the American Heart Association . 2013,第11期

机译：Acostolakis等人关于文章的信，“肾功能障碍是非衰弱性心房颤动患者中风和全身栓塞的预测因子：验证R（2）牧草（2）指数在火箭AF中的指数（Rivaroxaban曾经每日，口服，与维生素K拮抗剂相比，直接因子XA抑制预防心房颤动中的中风和栓塞试验）和阿里亚（心房颤动的抗凝和危险因素）研究队列“
4. Impact of three dimensional atrial fibrosis on development and stability of rotational and focal sources in atrial fibrillation — A 3D simulation and clinical high-density mapping study in persistent atrial fibrillation [C] . Markus Rottmann, Viktor Markstein, Ufuk Arslan, Computing in Cardiology Conference . 2016

机译：三维房颤对房颤中旋转和局灶性源的发展和稳定性的影响—持续性房颤的3D模拟和临床高密度标测研究
5. The influence of socioeconomic status on selection of anticoagulation for atrial fibrillation: A population based study. [D] . Sholzberg, Michelle. 2016

机译：社会经济状况对房颤抗凝药物选择的影响：一项基于人群的研究。
6. Stroke Risk Status Anticoagulation Treatment and Quality-of-Life in Chinese Patients with Atrial Fibrillation: China Registry of Atrial Fibrillation (CRAF) [O] . Yihong Sun, Jun Zhu, Changsheng Ma, 2019

机译：中国房颤患者的中风风险状况抗凝治疗和生活质量：中国房颤注册中心（CRAF）
7. GW26-e2303 Suboptimal oral anticoagulation use among Chinese nonvalvular Atrial Fibrillation Patients: the Nanchang Atrial Fibrillation project [O] . Xiong Qinmei, Shantsila Alena, Cheng Xiaoshu, 2015

机译：GW26-e2303在中国非瓣膜性房颤患者中口服抗凝治疗效果欠佳：南昌房颤项目

Current Status and Time Trends of Oral Anticoagulation Use Among Chinese Patients With Nonvalvular Atrial Fibrillation:The Chinese Atrial Fibrillation Registry Study

著录项

引文网络

相似文献

相关主题

期刊订阅